Cardiovascular activity of WIN 65579, a novel inhibitor of cyclic GMP phosphodiesterase 5

European Journal of Pharmacology

Volumn 349, Issue 2-3, 1998, Pages 263-268

  Silver, Paul J ^a   Pagani, Edward D ^a   Dundore, Ronald L ^a   De Garavilla, Lawrence ^a   Bode, D Chris ^a   Bacon, Edward R ^a  

^a Sterling Winthrop ^*  (United States)

Author keywords

Cardiovascular; cGMP; Nitric oxide (NO); Nitroglycerin; Phosphodiesterase

Indexed keywords

1 CYCLOPENTYL 3 ETHYL 6 (3 ETHOXY 4 PYRIDYL) 1H PYRAZOLO[3,4 D]PYRIMIDIN 4 ONE; CYCLIC GMP; CYCLIC GMP PHOSPHODIESTERASE; GLYCERYL TRINITRATE; ISOENZYME; PHOSPHODIESTERASE INHIBITOR; UNCLASSIFIED DRUG; WIN 65579;

ANIMAL TISSUE; AORTA; ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DOG; DRUG SENSITIZATION; ENDOTHELIUM; ENZYME INHIBITION; IN VITRO STUDY; INTRAVENOUS DRUG ADMINISTRATION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; VASOCONSTRICTION;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ANIMALS; AORTA; BLOOD PRESSURE; CYCLIC GMP; HEART RATE; MALE; MUSCLE RELAXATION; MUSCLE, SMOOTH, VASCULAR; NITROGLYCERIN; PHOSPHODIESTERASE INHIBITORS; PURINONES; PYRIMIDINES; RATS; RATS, INBRED SHR;

EID: 0032557584     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00209-X     Document Type: Article

References (19)

1. Beavo J.A., Conti M., Heaslip R.J. Multiple cyclic nucleotide phosphodiesterases. Mol. Pharmacol. 46:1994;399-405.
2. de Garavilla L., Pagani E.D., Buchholz R.A., Dundore R.L., Bode D.C., Volberg M.L., Jackson K.N., Pratt P.F., Silver P.J. Zaprinast, but not dipyridamole reverses hemodynamic tolerance to nitroglycerin in vivo. Eur. J. Pharmacol. 313:1996;89-96.
3. de Garavilla L., Volberg M.L., Pratt P.F., Silver P.J., Buchholz R.A. Lack of cross-tolerance between nitroglycerin and endothelium- derived relaxing factor- mediated vasoactive agents in spontaneously hypertensive rats. Eur. J. Pharmacol. 234:1993;77-82.
4. Dundore R.L., Clas D.M., Wheeler L.T., Habeeb P.G., Bode D.C., Buchholz R.A., Silver P.J., Pagani E.D. Zaprinast increases cyclic GMP levels in plasma and in aortic tissue of rats. Eur. J. Pharmacol. 249:1993;293-297.
5. ω-nitro-L-arginine attenuates the accumulation of aortic cyclic GMP and the hypotension produced by zaprinast. Eur. J. Pharmacol. 200:1991;83-87.
6. Harris A.L., Lemp B.M., Bentley R.G., Perrone M.H., Hamel L.T., Silver P.J. Phosphodiesterase isozyme inhibition and the potentiation by zaprinast of endothelium-derived relaxing factor and guanylate cyclase stimulating agents in vascular smooth muscle. J. Pharmacol. Exp. Ther. 249:1989;394-400.
7. Kariya K.I., Kawahara Y., Araki S.I., Fukuzaki H., Takai Y. Antiproliferative action of cyclic GMP-elevating vasodilators in cultured rabbit aortic muscle cells. Atherosclerosis. 80:1989;143-147.
8. Loughney, K., Ferguson,K., 1996. Identification and quantification of phosphodiesterase isoenzymes and subtypes by molecular biological methods. In: Schudt, C., Dent, G., Rabe, K.F. (Eds.), Phosphodiesterase Inhibitors. Academic Press, London, pp. 1-19.
9. Martin W., Furchgott R.F., Villani G.M., Jothianandan D. Phosphodiesterase inhibitors induce endothelial-dependent relaxation of rat and rabbit aorta by spontaneously released endothelium-derived relaxing factor. J. Pharmacol. Exp. Ther. 237:1986;539-547.
10. McMahon E.G., Palomo M.A., Mehta P., Olins G.M. Depressor and natriuretic effects of M and B 22,948, a guanosine cyclic 3′,5′-monophosphate-selective phosphodiesterase inhibitor. J. Pharmacol. Exp. Ther. 251:1989;1000-1005.
11. Murad F. Cyclic guanosine monophosphate as a mediator of vasodilation. J. Clin. Invest. 78:1986;1-5.
12. Pagani, E.D., Buchholz, R.A., Silver, P.J., 1992. Cardiovascular cyclic nucleotide phosphodiesterases and their role in regulating cardiovascular function. In: Hasenfuss, G., Holubarsch, C., Just, H., Alpert, N. (Eds.), Cellular and Molecular Alterations in the Failing Human Heart. Darmstadt Springer, New York, NY, pp. 73-86.
13. Radomski M.W., Palmer R.M.J., Moncada S. Characterization of the L-arginine: nitric oxide pathway in human platelets. Br. J. Pharmacol. 101:1990;325-328.
14. Rafjer J., Aronson W.J., Bush P.A., Dorey F.J., Ignarro L.J. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N. Engl. J. Med. 326:1992;90-94.
15. Saeki T., Adachi H., Takase Y., Yoshitake S., Souda S., Saito I. A selective type V phosphodiesterase inhibitor, E4021, dilates porcine large coronary artery. J. Pharmacol. Exp. Ther. 272:1995;825-831.
16. Silver, P.J., 1996. Inhibition of phosphodiesterase isoenzymes and cell function by selective phosphodiesterase 5 inhibitors, In: Schudt, C., Dent, G., Rabe, K.F. (Eds.), Phosphodiesterase Inhibitors, Academic Press, London, pp. 127-134.
17. Silver P.J., Dundore R.L., Bode D.C., de Garavilla L., Buchholz R.A., van Aller G., Hamel L.T., Bacon E.R., Singh B., Lesher G.Y., Hlasta D., Pagani E.D. Cyclic GMP potentiation by WIN 58237, a novel cyclic nucleotide phosphodiesterase inhibitor. J. Pharmacol. Exp. Ther. 271:1994;1143-1149.
18. Tallarida, R.J., Murray, R.B., 1987. Manual of Pharmacological Calculations. Springer, New York.
19. Terrett N.K., Bell A.S., Brown D., Ellis P. Sildenafil (VIAGRA™), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction. Bioorg. Med. Chem. Lett. 6:1996;1819-1823.